Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Other Non-Current Liabilities: 2022-2023

Historic Other Non-Current Liabilities for NewAmsterdam Pharma Co N.V (NAMS) over the last 2 years, with Dec 2023 value amounting to $7.8 million.

  • NewAmsterdam Pharma Co N.V's Other Non-Current Liabilities was N/A to $18.8 million in Q3 2024 from the same period last year, while for Sep 2024 it was $18.8 million, marking a year-over-year change of. This contributed to the annual value of $7.8 million for FY2023, which is 3.54% up from last year.
  • Latest data reveals that NewAmsterdam Pharma Co N.V reported Other Non-Current Liabilities of $7.8 million as of FY2023, which was up 3.54% from $7.5 million recorded in FY2022.
  • NewAmsterdam Pharma Co N.V's Other Non-Current Liabilities' 5-year high stood at $7.8 million during FY2023, with a 5-year trough of $7.5 million in FY2022.
  • Over the past 2 years, NewAmsterdam Pharma Co N.V's median Other Non-Current Liabilities value was $7.7 million (recorded in 2022), while the average stood at $7.7 million.
  • Data for NewAmsterdam Pharma Co N.V's Other Non-Current Liabilities shows a peak YoY climbed of 3.54% (in 2023) over the last 5 years.
  • Over the past 2 years, NewAmsterdam Pharma Co N.V's Other Non-Current Liabilities (Yearly) stood at $7.5 million in 2022, then rose by 3.54% to $7.8 million in 2023.